Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biodexa Pharmaceticals (BDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BDRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.99% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.80M USD | Price to earnings Ratio - | 1Y Target Price 18.58 |
Price to earnings Ratio - | 1Y Target Price 18.58 | ||
Volume (30-day avg) 2320088 | Beta 1.5 | 52 Weeks Range 1.14 - 74.00 | Updated Date 04/2/2025 |
52 Weeks Range 1.14 - 74.00 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -77.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7931.33% |
Management Effectiveness
Return on Assets (TTM) -37.52% | Return on Equity (TTM) -97.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5235064 | Price to Sales(TTM) 9.67 |
Enterprise Value -5235064 | Price to Sales(TTM) 9.67 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 668592 | Shares Floating 2256673297 |
Shares Outstanding 668592 | Shares Floating 2256673297 | ||
Percent Insiders 8.82 | Percent Institutions 29.86 |
Analyst Ratings
Rating 5 | Target Price 17.46 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biodexa Pharmaceticals
Company Overview
History and Background
Biodexa Pharmaceuticals PLC, formerly known as Nemaura Medical Inc., is a biopharmaceutical company focused on developing products for chronic diseases. Founded in 2009, they initially focused on glucose monitoring before pivoting to therapeutics. Significant milestones include clinical trials and strategic acquisitions.
Core Business Areas
- Drug Development: Development of innovative therapies for chronic diseases.
- Drug Delivery Systems: Utilizing proprietary drug delivery technologies to improve therapeutic outcomes.
Leadership and Structure
The company is led by a board of directors and an executive management team overseeing research and development, clinical operations, and business strategy.
Top Products and Market Share
Key Offerings
- MTX110: A formulation of methotrexate for treating solid tumors that has received orphan drug designation in the US, the EU, and Australia. Biodexa is preparing to initiate a Phase 2 clinical trial. Competitors include companies developing other methotrexate formulations and alternative treatments for solid tumors.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Innovation in drug delivery is a key area of focus.
Positioning
Biodexa aims to differentiate itself through its proprietary drug delivery technologies and focus on orphan drug designations. Their competitive advantage lies in targeted therapies for unmet medical needs.
Total Addressable Market (TAM)
TAM for Biodexa's target indications varies depending on the specific disease and treatment. The company is positioned to capture a portion of this market through successful clinical development and commercialization of its products. No specific number can be provided without detailed market analysis for individual drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies
- Orphan drug designations
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Early-stage development pipeline
- Dependence on key partnerships
Opportunities
- Strategic partnerships and collaborations
- Expansion into new therapeutic areas
- Accelerated regulatory pathways for orphan drugs
- Growing demand for targeted therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- MRTX
- LLY
- BMY
Competitive Landscape
Biodexa faces strong competition from established pharmaceutical companies with greater resources and broader pipelines. Biodexa's success depends on differentiating its products through superior efficacy and targeted delivery.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not currently available.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for MTX110 and seeking strategic partnerships.
Summary
Biodexa Pharmaceticals is a developing biopharmaceutical company with a focus on targeted therapies for unmet medical needs. Its strengths lie in its proprietary drug delivery technologies and orphan drug designations. The company faces risks associated with clinical trial success and competition from larger pharmaceutical companies. Strategic partnerships and successful clinical development are crucial for future growth.
Similar Companies
ARVN
Arvinas Inc
ARVN
Arvinas Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NKTR
Nektar Therapeutics
NKTR
Nektar Therapeutics
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodexa Pharmaceticals
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-12-07 | CEO, CFO, Company Secretary & Director Mr. Stephen Anthony Stamp | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://www.biodexapharma.com |
Full time employees 21 | Website https://www.biodexapharma.com | ||
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.